Innate Pharma (IPHA) announced that it has entered into an exclusive license agreement with Takeda (TAK) under which Innate grants Takeda exclusive worldwide rights to research and develop antibody drug conjugates, or ADC, using a panel of selected Innate antibodies against an undisclosed target, with a primary focus in Celiac disease. Takeda will be responsible for the future development, manufacture and commercialization of any potential products developed using the licensed antibodies.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on IPHA:
